MedTrace Logo

Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

NCT00509184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2020-01-06

No results posted yet for this study

Summary

Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.

Conditions

  • Lymphoma, Malignant

Interventions

DRUG

Rituximab

375 mg/m\^2, weekly (4 weeks), repeated after 4 weeks gap

Sponsors & Collaborators

  • German Low Grade Lymphoma Study Group

    collaborator OTHER

  • Roche Pharma AG

    collaborator INDUSTRY

  • Klaus Herfarth, MD

    lead OTHER

Principal Investigators

  • Klaus Herfarth, MD · Heidelberg University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509184 on ClinicalTrials.gov